Safety, Tolerability and Antimalarial Activity of Single Doses of OZ439 and PQP
Status:
Completed
Trial end date:
2019-04-19
Target enrollment:
Participant gender:
Summary
A single-centre Phase 1b study to assess the safety, tolerability, pharmacokinetic profile,
and antimalarial activity of single doses of coadministered artefenomel (OZ439) and
piperaquine phosphate (PQP) against early Plasmodium falciparum blood stage infection in
healthy adult volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Medicines for Malaria Venture
Collaborators:
Clinical Network Services (CNS) Pty Ltd Q-Pharm Pty Limited QIMR Berghofer Medical Research Institute
Treatments:
alpha-Tocopherol Antimalarials Piperaquine Tocopherols Tocotrienols Vitamin E